Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and delivering innovative therapies for central nervous system (CNS) disorders. Based in New York City, Axsome focuses on addressing the significant unmet medical needs of patients suffering from conditions such as major depressive disorder and migraines, among others. The company's team consists of dynamic professionals committed to enhancing patient outcomes through their research and development efforts. With a strong emphasis on collaboration and integrity, Axsome aims to bring new treatment options to market that can make a meaningful difference in the lives of patients. The organization values a culture of excellence and innovation, fostering an environment where employees can thrive and contribute to the greater mission of transforming CNS treatment.